Moors & Cabot’s Bristol-Myers Squibb BMY Stock Holding History

Moors & Cabot’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.11M	Sell	67,840 -7,360	-10%	-$429K	0.18%	122
2025 Q4	$4.06M	Buy	75,200 +6,385	+9%	+$307K	0.17%	122
2025 Q3	$3.1M	Sell	68,815 -5,134	-7%	-$240K	0.14%	143
2025 Q2	$3.42M	Sell	73,949 -3,634	-5%	-$178K	0.16%	126
2025 Q1	$4.73M	Sell	77,583 -11,646	-13%	-$679K	0.24%	89
2024 Q4	$5.05M	Buy	89,229 +11,578	+15%	+$647K	0.24%	84
2024 Q3	$4.02M	Sell	77,651 -7,454	-9%	-$350K	0.2%	103
2024 Q2	$3.53M	Sell	85,105 -15,884	-16%	-$711K	0.19%	111
2024 Q1	$5.48M	Buy	100,989 +1,677	+2%	+$85.4K	0.3%	73
2023 Q4	$5.1M	Sell	99,312 -7,082	-7%	-$372K	0.32%	71
2023 Q3	$6.18M	Sell	106,394 -1,418	-1%	-$86.9K	0.42%	47
2023 Q2	$6.89M	Buy	107,812 +1,753	+2%	+$118K	0.46%	44
2023 Q1	$7.35M	Buy	106,059 +1,855	+2%	+$131K	0.51%	38
2022 Q4	$7.5M	Buy	104,204 +2,785	+3%	+$210K	0.52%	38
2022 Q3	$7.21M	Buy	101,419 +812	+0.8%	+$58.9K	0.55%	36
2022 Q2	$7.75M	Sell	100,607 -3,038	-3%	-$231K	0.56%	35
2022 Q1	$7.57M	Buy	103,645 +1,740	+2%	+$117K	0.47%	43
2021 Q4	$6.35M	Sell	101,905 -3,337	-3%	-$196K	0.39%	60
2021 Q3	$6.25M	Buy	105,242 +1,871	+2%	+$123K	0.39%	54
2021 Q2	$6.91M	Sell	103,371 -8,974	-8%	-$585K	0.48%	43
2021 Q1	$7.1M	Sell	112,345 -6,554	-6%	-$408K	0.54%	37
2020 Q4	$7.39M	Buy	118,899 +3,728	+3%	+$229K	0.62%	27
2020 Q3	$6.94M	Buy	115,171 +2,804	+2%	+$169K	0.65%	28
2020 Q2	$6.63M	Buy	112,367 +13,818	+14%	+$826K	0.71%	26
2020 Q1	$5.51M	Sell	98,549 -6,827	-6%	-$417K	0.8%	22
2019 Q4	$6.75M	Sell	105,376 -13,447	-11%	-$770K	0.68%	30
2019 Q3	$6.01M	Buy	118,823 +10,150	+9%	+$477K	0.66%	30
2019 Q2	$4.94M	Buy	108,673 +42,926	+65%	+$2M	0.63%	32
2019 Q1	$3.15M	Buy	65,747 +5,909	+10%	+$294K	0.43%	60
2018 Q4	$3.11M	Sell	59,838 -2,061	-3%	-$111K	0.49%	50
2018 Q3	$3.84M	Sell	61,899 -1,893	-3%	-$112K	0.47%	51
2018 Q2	$3.54M	Sell	63,792 -3,259	-5%	-$176K	0.48%	52
2018 Q1	$4.24M	Sell	67,051 -12,362	-16%	-$795K	0.56%	38
2017 Q4	$4.86M	Sell	79,413 -896	-1%	-$56K	0.64%	32
2017 Q3	$5.12M	Buy	80,309 +4,195	+6%	+$245K	0.74%	22
2017 Q2	$4.25M	Buy	76,114 +3,235	+4%	+$176K	0.71%	25
2017 Q1	$3.96M	Buy	72,879 +1,458	+2%	+$80K	0.67%	28
2016 Q4	$4.19M	Buy	71,421 +11,765	+20%	+$643K	0.69%	24
2016 Q3	$3.22M	Buy	59,656 +1,501	+3%	+$96.4K	0.54%	43
2016 Q2	$4.28M	Buy	58,155 +2,453	+4%	+$173K	0.75%	22
2016 Q1	$3.56M	Buy	55,702 +1,375	+3%	+$86.7K	0.64%	29
2015 Q4	$3.75M	Sell	54,327 -1,764	-3%	-$117K	0.69%	25
2015 Q3	$3.33M	Buy	56,091 +2,066	+4%	+$131K	0.62%	34
2015 Q2	$3.59M	Buy	54,025 +590	+1%	+$38.9K	0.58%	38
2015 Q1	$3.44M	Buy	53,435 +135	+0.3%	+$8.45K	0.57%	38
2014 Q4	$3.16M	Sell	53,300 -2,880	-5%	-$162K	0.54%	41
2014 Q3	$2.86M	Sell	56,180 -1,150	-2%	-$57.4K	0.49%	47
2014 Q2	$2.8M	Buy	57,330 +12,446	+28%	+$613K	0.47%	51
2014 Q1	$2.33M	Buy	+44,884	New	+$2.39M	0.59%	45

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Moors & Cabot's BMY Position: Q1 2026 in Review

Moors & Cabot reduced its Bristol-Myers Squibb (BMY) stake by 9.8% in Q1 2026, selling an estimated $429K and leaving 67,840 shares worth $4.11M. The position accounts for 0.18% of the portfolio, ranked #122.

Moors & Cabot first reported a position in BMY in Q1 2014 and has held it in 49 quarters since. The position peaked at $7.75M in Q2 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Moors & Cabot held 67,840 shares of Bristol-Myers Squibb worth $4.11M as of Q1 2026.
Moors & Cabot sold 7,360 Bristol-Myers Squibb shares in Q1 2026, an estimated $429K.
Bristol-Myers Squibb made up 0.18% of Moors & Cabot's portfolio in Q1 2026, its #122 holding.
Moors & Cabot first reported a position in Bristol-Myers Squibb in Q1 2014 and has held it in 49 quarters since.
Moors & Cabot's Bristol-Myers Squibb position peaked at $7.75M in Q2 2022.
2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.